Geographic Atrophy

Avacincaptad pegol shows promising vision loss reduction in geographic atrophy

In a post hoc time-to-event analysis, there was a 59% risk reduction in the rate of vision loss in patients treated with avacincaptad pegol compared to sham at 12 months, according to a press release. The GATHER1 and GATHER2 clinical trials were designed to evaluate the rate of geographic atrophy...